Wang Yanping, Jing Miao, Hua Ying, Zhang Lin, Wang Jianbiao, Fan Xiaochun
Department of Neurology, The Affiliated Wuxi Children's Hospital of JiangNan University, Wuxi, Jiangsu Province, China.
Department of Emergency, Wuxi No.2 People's Hospital, Wuxi, Jiangsu Province, China.
Front Pediatr. 2025 Apr 16;13:1549103. doi: 10.3389/fped.2025.1549103. eCollection 2025.
To investigate the clinical efficacy of Shaoma Zhijing Granules in treating pediatric tic disorders and its impact on plasma neurotransmitter levels.
Eighty pediatric patients with tic disorders were randomly divided into the Shaoma Zhijing group (40 cases) and the Tiapride group (40 cases). The Yale Global Tic Severity Scale (YGTSS) scores, clinical efficacy, and traditional Chinese medicine (TCM) syndrome evaluations were compared at baseline, 4 weeks, and 8 weeks after treatment. Ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to analyze the changes in plasma neurotransmitter levels before and after treatment.
Compared with baseline, both groups showed a decrease in YGTSS scores and TCM syndrome scores at 4 weeks and 8 weeks after treatment ( < 0.05). No statistically significant differences were observed between the two groups ( > 0.05). The effective rates were 90% for the Shaoma Zhijing group and 80% for the Tiapride group, with the incidence of adverse reactions being 2.5% and 15%, respectively. After 8 weeks, serum levels of glutamic acid (Glu), aspartic acid (Asp), dopamine (DA), norepinephrine (NE), and epinephrine (E) in both groups were significantly lower than baseline ( < 0.05), while gamma-aminobutyric acid (GABA) levels were significantly higher ( < 0.05). Significant differences were also observed between the two groups in DA, NE, E, and GABA levels after treatment ( < 0.05).
Shaoma Zhijing Granules demonstrate significant clinical efficacy and good safety in treating pediatric tic disorders. They effectively improve symptoms, thereby contributing to the enrichment of the TCM diagnostic and treatment system for pediatric tic disorders.
探讨芍麻止痉颗粒治疗小儿抽动障碍的临床疗效及其对血浆神经递质水平的影响。
将80例小儿抽动障碍患者随机分为芍麻止痉组(40例)和硫必利组(40例)。比较两组治疗前、治疗4周及8周后的耶鲁综合抽动严重程度量表(YGTSS)评分、临床疗效及中医证候评价。采用超高效液相色谱-串联质谱法(UPLC-MS/MS)分析治疗前后血浆神经递质水平的变化。
与基线相比,两组治疗4周和8周时YGTSS评分及中医证候评分均降低(<0.05)。两组间差异无统计学意义(>0.05)。芍麻止痉组有效率为90%,硫必利组为80%,不良反应发生率分别为2.5%和15%。治疗8周后,两组血清谷氨酸(Glu)、天冬氨酸(Asp)、多巴胺(DA)、去甲肾上腺素(NE)和肾上腺素(E)水平均显著低于基线(<0.05),而γ-氨基丁酸(GABA)水平显著升高(<0.05)。治疗后两组DA、NE、E及GABA水平差异也有统计学意义(<0.05)。
芍麻止痉颗粒治疗小儿抽动障碍临床疗效显著,安全性好。能有效改善症状,为小儿抽动障碍的中医诊疗体系增添内容。